Skip to main content
Kadimastem Ltd. logo

Kadimastem Ltd. — Investor Relations & Filings

Ticker · KDST ISIN · IL0011284614 TA Professional, scientific and technical activities
Open in API
Filings indexed 20 across all filing types
Latest filing 2025-10-29 Delisting Announcement
Country IL Israel
Listing TA KDST

About Kadimastem Ltd.

https://www.kadimastem.com/

Kadimastem is a clinical-stage cell therapy company that develops and manufactures "off-the-shelf" allogeneic cell products. The company utilizes a proprietary technology platform to differentiate human pluripotent stem cells into functional cells for treating diseases. Its lead clinical program, AstroRx®, is an astrocyte cell therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Kadimastem is also advancing a preclinical program for Type 1 Diabetes with IsletRx, a product consisting of stem cell-derived pancreatic islet cells intended to restore the body's ability to produce and regulate insulin. The company's focus is on creating regenerative medicine solutions for conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Delisting of Securities from Trade on the Tel Aviv Stock Exchange on October 31, 2025
Delisting Announcement Classification · 100% confidence The document is a short notice from the Tel Aviv Stock Exchange (TASE) informing members that Kadimastem Ltd shares will be delisted on October 31, 2025, following a merger. It explicitly mentions the delisting date and the suspension of trading. This fits the definition of a Delisting Announcement.
2025-10-29 English
Company Presentation
Investor Presentation Classification · 98% confidence The document is a detailed presentation containing slides, figures, market data, clinical trial results (Phase 1/2a for AstroRx®), pipeline information, and future plans (RMAT designation application, Phase IIa trial commencement). The content is highly focused on presenting the company's technology, scientific rationale, and progress to investors or stakeholders. This format strongly aligns with an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER) or a simple announcement of a report (RPA).
2024-05-28 English
Company Presentation
AGM Information Classification · 98% confidence The document text contains Hebrew characters and appears to be a regulatory filing or announcement from KADIMASTEM LTD, referencing the Israeli Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The title section explicitly states: "**���� ������:** ***���� ���� ����� ������ ���� ������� ��������� ���� �� ���� ������ ������***" which translates roughly to "**Document Title:** ***Announcement regarding the convening of an Annual General Meeting***". Furthermore, it mentions a presentation file named *Kadimastem_Presentation_May_2024_isa.pdf* and details about the meeting date (27/05/2024). This strongly indicates materials related to the Annual General Meeting (AGM). Therefore, the classification should be AGM-R.
2024-05-28 Russian
Excellence Investments Management and Securities will cease to operate as a market maker in the company's shares starting from February 29, 2024
Regulatory Filings Classification · 95% confidence The document is a notification from the Tel Aviv Stock Exchange about the discontinuation of market making for a specific security (KADIMASTEM). It is an official announcement regarding trading activity rather than a financial report, management change, or other detailed filings. The content is brief and focused on a specific market activity update, which fits the category of a Regulatory Filing (RNS) as it does not match any other more specific category such as capital changes, delisting, or director dealings.
2024-02-12 Hebrew (modern)
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
Capital/Financing Update Classification · 95% confidence The document announces details about a rights offering for Kadimastem, including trading dates for ex-rights shares and identifying details for new securities. It focuses on capital structure changes related to rights offerings and new security identifiers. There is no indication of a full report, financial statements, or management discussion. The content fits the category of Capital/Financing Update, which covers company fundraising and capital structure changes.
2022-12-13 Hebrew (modern)
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
Regulatory Filings Classification · 100% confidence The document is a press release dated August 9, 2022, announcing that Kadimastem has received a US Patent for its ALS treatment technology. It contains company updates, product information (AstroRx®), clinical trial progress, market size estimates, and forward-looking statements. This type of announcement, which disseminates significant corporate news outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or press releases. Since there is no specific category for 'Patent Grant Announcement' and it is not a formal financial report, earnings release, or management change, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory news disseminated via services like DGAP.
2022-08-09 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.